Published in Vaccine Weekly, November 2nd, 1998
"Evaluating human immune response to defined Mycobacterium tuberculosis antigens in patients with different clinical forms of tuberculosis may help in elucidating pathogenesis and in vaccine development," S. Arruda and colleagues wrote ("Cell-Mediated Immune Responses and Cytotoxicity to Mycobacterial Antigens in Patients with Tuberculous Pleurisy in Brazil," Acta Trop, August 15, 1998;71(1):1-15).
"In the present report we evaluated the lymphocyte proliferation, cytokine production and natural killer cell cytotoxicity as parameters to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1998-11-02)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.